Compare CIO & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CIO | NGNE |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.5M | 327.8M |
| IPO Year | 2014 | N/A |
| Metric | CIO | NGNE |
|---|---|---|
| Price | $6.99 | $18.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | N/A | ★ $38.50 |
| AVG Volume (30 Days) | ★ 347.5K | 165.8K |
| Earning Date | 02-19-2026 | 11-13-2025 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $163,795,000.00 | N/A |
| Revenue This Year | $0.32 | N/A |
| Revenue Next Year | $3.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.19 | $6.88 |
| 52 Week High | $7.01 | $37.27 |
| Indicator | CIO | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 67.11 | 39.16 |
| Support Level | $6.94 | $19.28 |
| Resistance Level | $6.97 | $22.99 |
| Average True Range (ATR) | 0.01 | 1.48 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 90.00 | 8.43 |
City Office REIT Inc is a real estate investment trust. It is focused on acquiring, owning, and operating high-quality office properties located predominantly in Sun Belt markets. The principal objective of the company is to provide attractive risk-adjusted returns to its investors over the long-term through a combination of dividends and capital appreciation. Its properties includes: Pima Center, SanTan, Park Tower, Intellicenter, Intellicenter, Denver Tech, Canyon Park, AmberGlen and many. The company own these office buildings in the metropolitan areas of Dallas, Denver, Orlando, Phoenix, Portland, Raleigh, San Diego, Seattle, and Tampa.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.